financetom
Business
financetom
/
Business
/
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
Nov 15, 2024 12:44 PM

07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results.

The trial met its key secondary endpoint of overall survival, demonstrating that the combination therapy "significantly reduced" the risk of death compared with the standard of care, daratumumab plus BorDex.

The full trial results, including safety data, will be presented at the upcoming American Society of Hematology Annual Meeting on Dec. 9.

The company will share the data with health authorities to support regulatory filings.

GSK said it plans to start a phase 3 study in newly diagnosed transplant-ineligible multiple myeloma by year-end as part of the DREAMM program.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Air Canada Down 3% as Swings to Profit in Q4
Update: Air Canada Down 3% as Swings to Profit in Q4
Feb 14, 2025
12:03 PM EST, 02/14/2025 (MT Newswires) -- (Updates shares.) Air Canada ( ACDVF ) late on Thursday said it swung to a profit in the fourth quarter. The airline reported its adjusted profit, excluding most one-time items, came in at $93 million, or $0.25 per share, compared with a loss of $44 million, or $0.12, in the year-prior quarter. Operating...
Zebra Technologies Cautious Amid Uncertainty Around Tariffs, Macro Economy, Morgan Stanley Says
Zebra Technologies Cautious Amid Uncertainty Around Tariffs, Macro Economy, Morgan Stanley Says
Feb 14, 2025
12:03 PM EST, 02/14/2025 (MT Newswires) -- Zebra Technologies ( ZBRA ) posted Q4 upside given a stronger-than-expected retail environment, but the company remains cautious heading into 2025 due to uncertainty around tariffs, the broader economy, and the strong dollar, Morgan Stanley said in a note late Thursday. The analysts said the demand environment for Zebra continued to improve in...
Airbnb's Q1 Room Night Guide Suggests Subdued Growth; Investment Initiatives Positive, RBC Says
Airbnb's Q1 Room Night Guide Suggests Subdued Growth; Investment Initiatives Positive, RBC Says
Feb 14, 2025
12:05 PM EST, 02/14/2025 (MT Newswires) -- Airbnb's ( ABNB ) Q1 room night outlook suggests subdued growth in booking volume following better-than-feared Q4 results, while its investment efforts this year are considered a positive factor, RBC Capital Markets said in a note emailed Friday. The company said late Thursday it was expecting nights and experiences booked in Q1 to...
Informatica Holds Limited Medium-Term Upside Following 'Messy' Q4, RBC Capital Says
Informatica Holds Limited Medium-Term Upside Following 'Messy' Q4, RBC Capital Says
Feb 14, 2025
12:03 PM EST, 02/14/2025 (MT Newswires) -- Informatica's ( INFA ) stock holds limited upside in the medium term after the software development company reported a messy/confusing Q4, missing expectations on most metrics except unlevered free cash flow, RBC Capital Markets said in a note Friday. Management cited sales execution issues and increased cloud modernization activity as key factors weighing...
Copyright 2023-2025 - www.financetom.com All Rights Reserved